Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Non-Current Deffered Revenue data on file, last reported at $34.1 million in Q2 2026.

• Quarterly Non-Current Deffered Revenue fell 58.92% year-over-year to $34.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $34.1 million (down 58.92% YoY) and the FY2025 annual result came in at $35.5 million, down 61.18% from the prior year.
• Non-Current Deffered Revenue retreated to $34.1 million in Q2 2026, from $34.3 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $115.1 million in Q2 2023 to a low of $34.1 million in Q2 2026.
• A 5-year average of $73.2 million and a median of $82.6 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue jumped 165.87% — and 2025, when it tumbled 61.18%.
• Tracing BCYC's Non-Current Deffered Revenue over 5 years: stood at $41.5 million in 2022, then soared by 165.87% to $110.2 million in 2023, then decreased by 17.01% to $91.5 million in 2024, then slumped by 61.18% to $35.5 million in 2025, then decreased by 4.03% to $34.1 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $34.1 million (Q2 2026), $34.3 million (Q1 2026), and $35.5 million (Q4 2025), per Business Quant data.